Background NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine
that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (…

Background Therapies for refractory cytomegalovirus infections (with or without resistance [R/R])
in transplant recipients are limited by toxicities. Maribavir has multimodal anti-…

Objective: To define the frequency and mortality rate associated with cytomegalovirus
infection in nonimmunosuppressed patients in the intensive care unit. Methods: A systematic …

(See the Editorial Commentary by Falagas and Rafailidis, on pages 681–3 .) Background.
Experience with intravenous and aerosolized forms of colistin for the treatment of ventilator-…

No therapeutic agent has yet been established as the definitive therapy for adenovirus infections.
We describe the clinical experience of 13 immunocompromised patients who received …

Hypogammaglobulinemia has been described after solid organ transplantation and has been
associated with increased risk of infections. The aim of the study was to evaluate the rate …

CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of
cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The …

Infections caused by adenoviruses are associated with significant morbidity and mortality in
both hematopoietic stem cell and solid organ transplant recipients. The risk seems to be …

We performed a concurrent comparison between solid organ transplant recipients and
nontransplant patients with blood culture–proven sepsis; after adjustments for clinical presentation…

From 2014 to May 2015, >26 000 Ebola virus disease (EVD) cases were reported from West
Africa. We present a patient with EVD who received brincidofovir and convalescent plasma. …